[8-K] Sarepta Therapeutics,, Inc. Reports Material Event
Sarepta Therapeutics announced the planned departure of Bilal Arif, its Executive Vice President and Chief Technical Operations Officer, as part of a strategic restructuring and pipeline prioritization. Mr. Arif served in the role through August 12, 2025, will remain a Special Advisor until his employment ends on September 16, 2025, and will provide consulting services through December 31, 2025. The company and Mr. Arif executed a Separation and Consulting Agreement dated August 12, 2025, under which he will receive a lump-sum severance payment of $576,700 and a consulting fee of $400 per hour. Outstanding equity awards will continue to vest while he remains employed or provides consulting services. The full agreement will be filed as an exhibit to the Company鈥檚 Quarterly Report for the quarter ended September 30, 2025.
Sarepta Therapeutics ha annunciato l'uscita pianificata di Bilal Arif, suo Executive Vice President e Chief Technical Operations Officer, nell'ambito di una ristrutturazione strategica e della ridefinizione delle priorit脿 della pipeline. Il sig. Arif ha ricoperto il ruolo fino al 12 agosto 2025, rester脿 Consulente Speciale fino alla cessazione del rapporto di lavoro il 16 settembre 2025 e fornir脿 servizi di consulenza fino al 31 dicembre 2025. La societ脿 e il sig. Arif hanno sottoscritto un Accordo di Separazione e Consulenza datato 12 agosto 2025, in base al quale ricever脿 un pagamento una tantum di $576,700 come indennit脿 e un compenso di consulenza di $400 all'ora. Le attribuzioni azionarie in essere continueranno a maturare mentre sar脿 ancora dipendente o fornir脿 consulenza. L'intero accordo sar脿 depositato come allegato al Rapporto Trimestrale della Societ脿 relativo al trimestre chiuso il 30 settembre 2025.
Sarepta Therapeutics anunci贸 la salida planificada de Bilal Arif, su Executive Vice President y Chief Technical Operations Officer, como parte de una reestructuraci贸n estrat茅gica y la priorizaci贸n de la cartera. El Sr. Arif ocup贸 el cargo hasta el 12 de agosto de 2025, permanecer谩 como Asesor Especial hasta la finalizaci贸n de su empleo el 16 de septiembre de 2025 y prestar谩 servicios de consultor铆a hasta el 31 de diciembre de 2025. La compa帽铆a y el Sr. Arif firmaron un Acuerdo de Separaci贸n y Consultor铆a con fecha 12 de agosto de 2025, por el cual recibir谩 un pago 煤nico de $576,700 como indemnizaci贸n y una tarifa de consultor铆a de $400 por hora. Las adjudicaciones de acciones pendientes seguir谩n consolid谩ndose mientras permanezca empleado o preste servicios de consultor铆a. El acuerdo completo se presentar谩 como anexo al Informe Trimestral de la Compa帽铆a correspondiente al trimestre terminado el 30 de septiembre de 2025.
Sarepta Therapeutics電� 鞝勲灥鞝� 甑“臁办爼 氚� 韺岇澊頂勲澕鞚� 鞖办劆靾滌渼 臁办爼鞚� 鞚柬櫂鞙茧 鞝勲 瓴� 斓滉碃 旮办垹 鞖挫榿 毂呾瀯鞛愳澑 牍岆瀯 鞎勲Μ頂�(Bilal Arif)鞚� 鞓堨爼霅� 韲挫瀯鞚� 氚滍憸頄堨姷雼堧嫟. 鞎勲Μ頂� 鞌姅 2025雲� 8鞗� 12鞚缄箤歆� 頃措嫻 歆侅眳鞚� 靾橅枆頄堨溂氅�, 2025雲� 9鞗� 16鞚� 韲挫 鞁滌爯旯岇 韸闺硠 瓿犽(Special Advisor)鞙茧 雮碃 2025雲� 12鞗� 31鞚缄箤歆� 旎劋韺� 靹滊箘鞀るゼ 鞝滉车頃� 鞓堨爼鞛呺媹雼�. 須岇偓鞕� 鞎勲Μ頂� 鞌姅 2025雲� 8鞗� 12鞚检瀽 鞚挫 氚� 旎劋韺� 瓿勳暯(Separation and Consulting Agreement)鞚� 觳搓舶頄堨溂氅�, 鞚挫棎 霐半澕 鞚检嫓旮� 韲挫 鞙勲旮� $576,700鞕� 鞁滉皠雼� $400鞚� 旎劋韺� 牍勳毄鞚� 氚涥矊 霅╇媹雼�. 氙胳旮� 欤检嫕 氤挫儊鞚� 攴戈皜 鞛 欷戩澊瓯半倶 旎劋韺呾潉 鞝滉车頃橂姅 霃欖晥 瓿勳啀頃挫劀 氩犾姢韺呺惄雼堧嫟. 鞝勳泊 瓿勳暯靹滊姅 2025雲� 9鞗� 30鞚茧 毵堦皭霅橂姅 攵勱赴 氤搓碃靹滌潣 觳秬 氍胳劀搿� 鞝滌稖霅� 鞓堨爼鞛呺媹雼�.
Sarepta Therapeutics a annonc茅 le d茅part pr茅vu de Bilal Arif, son Executive Vice President et Chief Technical Operations Officer, dans le cadre d'une restructuration strat茅gique et de la priorisation de son pipeline. M. Arif a occup茅 ce poste jusqu'au 12 ao没t 2025, restera conseiller sp茅cial jusqu'脿 la fin de son emploi le 16 septembre 2025 et fournira des services de conseil jusqu'au 31 d茅cembre 2025. La soci茅t茅 et M. Arif ont conclu un accord de s茅paration et de conseil dat茅 du 12 ao没t 2025, selon lequel il recevra un paiement forfaitaire de $576,700 en indemnit茅 et des honoraires de conseil de $400 par heure. Les attributions d'actions en cours continueront 脿 锚tre acquises tant qu'il sera employ茅 ou qu'il fournira des services de conseil. L'accord complet sera d茅pos茅 en annexe au rapport trimestriel de la soci茅t茅 pour le trimestre clos le 30 septembre 2025.
Sarepta Therapeutics gab bekannt, dass Bilal Arif, Executive Vice President und Chief Technical Operations Officer, im Rahmen einer strategischen Umstrukturierung und Priorisierung der Pipeline planm盲脽ig ausscheidet. Herr Arif hatte die Position bis zum 12. August 2025 inne, bleibt bis zur Beendigung seines Arbeitsverh盲ltnisses am 16. September 2025 als Special Advisor t盲tig und wird bis zum 31. Dezember 2025 Beratungsleistungen erbringen. Das Unternehmen und Herr Arif haben am 12. August 2025 eine Trennungs- und Beratungsvereinbarung (Separation and Consulting Agreement) geschlossen, wonach er eine Abfindungszahlung in H枚he von $576,700 als Einmalbetrag sowie ein Honorar von $400 pro Stunde erh盲lt. Ausstehende Aktienzuteilungen werden weiter vesten, solange er angestellt ist oder Beratungsleistungen erbringt. Die vollst盲ndige Vereinbarung wird als Anlage zum Quartalsbericht des Unternehmens f眉r das zum 30. September 2025 endende Quartal eingereicht.
- Continuity preserved: Mr. Arif will consult through December 31, 2025, helping transition responsibilities.
- Equity alignment maintained: Outstanding equity awards will continue to vest while he is employed or consulting, preserving incentive alignment.
- Senior leadership departure: The company is losing its Executive Vice President, Chief Technical Operations Officer amid strategic restructuring.
- Separation cost disclosed: The agreement includes a lump-sum severance of $576,700 plus a consulting rate of $400 per hour.
Insights
TL;DR: Senior operations leader departs during restructuring; separation includes severance and consulting to preserve continuity.
The filing documents a controlled executive transition tied to a stated strategic restructuring and pipeline prioritization. The Separation and Consulting Agreement provides continuity by extending vesting of equity awards and retaining Mr. Arif as a consultant through December 31, 2025, which may limit short-term disruption. The agreement鈥檚 explicit cash severance of $576,700 and a consulting rate of $400/hour are material compensation details that investors can quantify. Impact assessment: Neutral given mitigation steps and disclosed terms.
TL;DR: Departure of Chief Technical Operations Officer is operationally significant but partially mitigated by consulting arrangement and continued equity vesting.
The departure of the Executive VP, Chief Technical Operations Officer, during a strategic reprioritization is an operational change that could affect technical programs. The company has secured consulting services through December 31, 2025 and continued vesting of outstanding equity awards while services continue, which preserves some leadership continuity and incentives. The disclosed financial terms鈥�$576,700 severance plus $400/hour consulting鈥攄efine the near-term cost of the transition. Impact assessment: Potentially impactful on operations but explicitly mitigated by the agreement.
Sarepta Therapeutics ha annunciato l'uscita pianificata di Bilal Arif, suo Executive Vice President e Chief Technical Operations Officer, nell'ambito di una ristrutturazione strategica e della ridefinizione delle priorit脿 della pipeline. Il sig. Arif ha ricoperto il ruolo fino al 12 agosto 2025, rester脿 Consulente Speciale fino alla cessazione del rapporto di lavoro il 16 settembre 2025 e fornir脿 servizi di consulenza fino al 31 dicembre 2025. La societ脿 e il sig. Arif hanno sottoscritto un Accordo di Separazione e Consulenza datato 12 agosto 2025, in base al quale ricever脿 un pagamento una tantum di $576,700 come indennit脿 e un compenso di consulenza di $400 all'ora. Le attribuzioni azionarie in essere continueranno a maturare mentre sar脿 ancora dipendente o fornir脿 consulenza. L'intero accordo sar脿 depositato come allegato al Rapporto Trimestrale della Societ脿 relativo al trimestre chiuso il 30 settembre 2025.
Sarepta Therapeutics anunci贸 la salida planificada de Bilal Arif, su Executive Vice President y Chief Technical Operations Officer, como parte de una reestructuraci贸n estrat茅gica y la priorizaci贸n de la cartera. El Sr. Arif ocup贸 el cargo hasta el 12 de agosto de 2025, permanecer谩 como Asesor Especial hasta la finalizaci贸n de su empleo el 16 de septiembre de 2025 y prestar谩 servicios de consultor铆a hasta el 31 de diciembre de 2025. La compa帽铆a y el Sr. Arif firmaron un Acuerdo de Separaci贸n y Consultor铆a con fecha 12 de agosto de 2025, por el cual recibir谩 un pago 煤nico de $576,700 como indemnizaci贸n y una tarifa de consultor铆a de $400 por hora. Las adjudicaciones de acciones pendientes seguir谩n consolid谩ndose mientras permanezca empleado o preste servicios de consultor铆a. El acuerdo completo se presentar谩 como anexo al Informe Trimestral de la Compa帽铆a correspondiente al trimestre terminado el 30 de septiembre de 2025.
Sarepta Therapeutics電� 鞝勲灥鞝� 甑“臁办爼 氚� 韺岇澊頂勲澕鞚� 鞖办劆靾滌渼 臁办爼鞚� 鞚柬櫂鞙茧 鞝勲 瓴� 斓滉碃 旮办垹 鞖挫榿 毂呾瀯鞛愳澑 牍岆瀯 鞎勲Μ頂�(Bilal Arif)鞚� 鞓堨爼霅� 韲挫瀯鞚� 氚滍憸頄堨姷雼堧嫟. 鞎勲Μ頂� 鞌姅 2025雲� 8鞗� 12鞚缄箤歆� 頃措嫻 歆侅眳鞚� 靾橅枆頄堨溂氅�, 2025雲� 9鞗� 16鞚� 韲挫 鞁滌爯旯岇 韸闺硠 瓿犽(Special Advisor)鞙茧 雮碃 2025雲� 12鞗� 31鞚缄箤歆� 旎劋韺� 靹滊箘鞀るゼ 鞝滉车頃� 鞓堨爼鞛呺媹雼�. 須岇偓鞕� 鞎勲Μ頂� 鞌姅 2025雲� 8鞗� 12鞚检瀽 鞚挫 氚� 旎劋韺� 瓿勳暯(Separation and Consulting Agreement)鞚� 觳搓舶頄堨溂氅�, 鞚挫棎 霐半澕 鞚检嫓旮� 韲挫 鞙勲旮� $576,700鞕� 鞁滉皠雼� $400鞚� 旎劋韺� 牍勳毄鞚� 氚涥矊 霅╇媹雼�. 氙胳旮� 欤检嫕 氤挫儊鞚� 攴戈皜 鞛 欷戩澊瓯半倶 旎劋韺呾潉 鞝滉车頃橂姅 霃欖晥 瓿勳啀頃挫劀 氩犾姢韺呺惄雼堧嫟. 鞝勳泊 瓿勳暯靹滊姅 2025雲� 9鞗� 30鞚茧 毵堦皭霅橂姅 攵勱赴 氤搓碃靹滌潣 觳秬 氍胳劀搿� 鞝滌稖霅� 鞓堨爼鞛呺媹雼�.
Sarepta Therapeutics a annonc茅 le d茅part pr茅vu de Bilal Arif, son Executive Vice President et Chief Technical Operations Officer, dans le cadre d'une restructuration strat茅gique et de la priorisation de son pipeline. M. Arif a occup茅 ce poste jusqu'au 12 ao没t 2025, restera conseiller sp茅cial jusqu'脿 la fin de son emploi le 16 septembre 2025 et fournira des services de conseil jusqu'au 31 d茅cembre 2025. La soci茅t茅 et M. Arif ont conclu un accord de s茅paration et de conseil dat茅 du 12 ao没t 2025, selon lequel il recevra un paiement forfaitaire de $576,700 en indemnit茅 et des honoraires de conseil de $400 par heure. Les attributions d'actions en cours continueront 脿 锚tre acquises tant qu'il sera employ茅 ou qu'il fournira des services de conseil. L'accord complet sera d茅pos茅 en annexe au rapport trimestriel de la soci茅t茅 pour le trimestre clos le 30 septembre 2025.
Sarepta Therapeutics gab bekannt, dass Bilal Arif, Executive Vice President und Chief Technical Operations Officer, im Rahmen einer strategischen Umstrukturierung und Priorisierung der Pipeline planm盲脽ig ausscheidet. Herr Arif hatte die Position bis zum 12. August 2025 inne, bleibt bis zur Beendigung seines Arbeitsverh盲ltnisses am 16. September 2025 als Special Advisor t盲tig und wird bis zum 31. Dezember 2025 Beratungsleistungen erbringen. Das Unternehmen und Herr Arif haben am 12. August 2025 eine Trennungs- und Beratungsvereinbarung (Separation and Consulting Agreement) geschlossen, wonach er eine Abfindungszahlung in H枚he von $576,700 als Einmalbetrag sowie ein Honorar von $400 pro Stunde erh盲lt. Ausstehende Aktienzuteilungen werden weiter vesten, solange er angestellt ist oder Beratungsleistungen erbringt. Die vollst盲ndige Vereinbarung wird als Anlage zum Quartalsbericht des Unternehmens f眉r das zum 30. September 2025 endende Quartal eingereicht.
FAQ
What change did Sarepta (SRPT) report regarding its executive team?
How much severance will Sarepta pay to Bilal Arif?
Will Mr. Arif鈥檚 equity awards continue to vest after his departure?
What consulting compensation will Mr. Arif receive?
Will Sarepta file the full separation agreement for investor review?
